69363-85-5

Basic information

• Product Name: METHYL 4-AMINOTHIOPHENE-3-CARBOXYLATE
• Synonyms: METHYL 4-AMINOTHIOPHENE-3-CARBOXYLATE;Methyl 4-aminothiophene-3-carboxylate, 95+%;3-Amino-4-thiophenecarboxylic acid methyl ester;3-THIOPHENECARBOXYLICACID,4-AMINO-,METHYLESTER;METHYL 3-AMINOTHIOPHENE-4-CARBOXYLATE;3-Thiophenecarboxylicacid, 4-amino-, methyl;4-Amino-thiophene-3-carboxylic acid methyl ester;3-Amino-4-(methoxycarbonyl)thiophene, Methyl 4-amino-3-thenoate
• CAS NO: 69363-85-5
• Molecular Formula: C₆H₇NO₂S
• Molecular Weight: 157.19
• Mol File: 69363-85-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 194-201 °C
• Boiling Point: 295.9 °C at 760 mmHg
• Flash Point: 132.8 °C
• Appearance: /
• Density: 1.319 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.89±0.10(Predicted)
• CAS DataBase Reference: METHYL 4-AMINOTHIOPHENE-3-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-AMINOTHIOPHENE-3-CARBOXYLATE(69363-85-5)
• EPA Substance Registry System: METHYL 4-AMINOTHIOPHENE-3-CARBOXYLATE(69363-85-5)

Safety Data

• Hazard Codes: Xi
• Safety Statements: S24/25:Avoid contact with skin and eyes.
• Hazardous Substances Data: 69363-85-5(Hazardous Substances Data)

Usage

General Description

Methyl 4-aminthiophene-3-carboxylate is a chemical compound with the molecular formula C7H9NO2S. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. METHYL 4-AMINOTHIOPHENE-3-CARBOXYLATE is known for its aromatic and sulfur-containing properties, making it useful in the production of various organic and medicinal compounds. It is also used as a building block in the synthesis of other valuable chemicals. Methyl 4-aminthiophene-3-carboxylate is important in the field of organic chemistry due to its versatile reactivity and ability to participate in various chemical reactions.

Upstream product

• 67-56-1 methanol 
• 26112-64-1 C₅H₅NO₂S 
• 7400-45-5 dimethyl-3-thiaadipate 
• 2689-68-1 methyl 4-oxotetrahydrothiophene-3-carboxylate 
• 39978-14-8 methyl 3-amino-4-thiophenecarboxylate hydrochloride 

Downstream Products

• 78071-37-1 4-bromo-3-thiophenecarboxylic acid methyl ester 
• 53826-78-1 methyl-4-formamido-3-thiophene carboxylate 
• 206192-43-0 4-(4-methoxy-benzenesulfonylamino)-thiophene-3-carboxylic acid methyl ester 
• 1042360-95-1 C₂₀H₁₆ClN₃O₃S₃ 
• 6251-30-5 thieno[3,4-d]pyrimidine-2,4(1H,3H)-dione 
• 1585969-89-6 methyl 4-([1,1'-biphenyl]-4-ylcarboxamido)thiophene-3-carboxylate 
• 233694-04-7 4-([1,1'-biphenyl]-4-ylcarboxamido)thiophene-3-carboxylic acid 
• 161940-20-1 methyl 4-((tert-butoxycarbonyl)amino)thiophene-3-carboxylate 
• 108180-63-8 4-((tert-butoxycarbonyl)amino)-3-thiophenecarboxylic acid 
• 110164-50-6 N-(3-carbomethoxythien-4-yl)-N-<2-<4-(2-methoxyphenyl)piperazin-1-yl>ethyl>urea dihydrochloride 

Relevant articles and documents

HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention are distinctive; possessing a particular class of halogenated heteroaryls. Such kinase inhibitors can display one or more certain properties distinct to dasatinib and other structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally similar kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions disclosed herein may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

Benzamidobenzoic acids as potent PqsD inhibitors for the treatment of Pseudomonas aeruginosa infections

Targeting PqsD is a promising novel approach to disrupt bacterial cell-to-cell-communication in Pseudomonas aeruginosa. In search of selective PqsD inhibitors, two series of benzamidobenzoic acids - one published as RNAP inhibitors and the other as PqsD inhibitors - were investigated for inhibitory activity toward the respective other enzyme. Additionally, novel derivatives were synthesized and biologically evaluated. By this means, the structural features needed for benzamidobenzoic acids to be potent and, most notably, selective PqsD inhibitors were identified. The most interesting compound of this study was the 3-Cl substituted compound 5 which strongly inhibits PqsD (IC 50 6.2 μM) while exhibiting no inhibition of RNAP.

ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS

The present invention discloses triazene analogs of the general formula (I) and formula (II), their tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts thereof for the metastatic malignant melanoma and other cancers including but not limited to lymphomas, sarcomas, carcinomas, and gliomas. The invention further discloses a process for the preparation of the above said triazene analogs of formula (I) and formula (II), and their pharmaceutically acceptable compositions.